At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 117 enrolled
Drug / intervention
Atazanavir/ritonavir monotherapydrug
Likely dose
Atazanavir/ritonavir monotherapy 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Atazanavir / Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression. Randomized, Open Label Non Inferiority Trial. A Phase 3 Study.
In Brief
A Phase 3 clinical trial evaluating Atazanavir/ritonavir monotherapy for HIV-1 Infection. Completed, enrolled 117 participants across 1 site.
Detailed Summary
The study will assess whether Atazanavir/ritonavir monotherapy provides a non-inferior proportion of virological efficacy with respect to ATV/RTV + 2 NRTIs in patients with stable suppressed viremia and no prior virologic failures.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1 Infection
CountriesItaly
CollaboratorsBristol-Myers Squibb
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedJan 2012
Primary CompletionJul 2013
Study CompletionMay 2015
TodayJul 2026
First PostedJan 19, 2012
Enrollment StartSep 1, 2010
Primary CompletionJul 1, 2013
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 14.5 years ago
Interventions
Atazanavir/ritonavir monotherapydrug
Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.